Cellectar Biosciences Announces Presentation Of Data On CLR 12120 Series Of Targeted Alpha-Emitting Therapies At The 13th Annual World ADC Conference
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the